Download PDF
Arthritis und Rheuma 2019; 39(04): 226-233
DOI: 10.1055/a-0950-1493
Schwerpunkt
© Georg Thieme Verlag KG Stuttgart · New York

Sicherheit von Antirheumatika in der Schwangerschaft: Empfehlungen von Embryotox

Safety of antirheumatic drugs in pregnancy: Recommendations of Embryotox
Corinna Weber-Schoendorfer∗
1   Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, und Berlin Institute of Health, Pharmakovigilanz- und Beratungszentrum Embryonaltoxikologie, Institut für Klinische Pharmakologie und Toxikologie
› Author Affiliations
Further Information

Publication History

Publication Date:
02 September 2019 (online)

    Permissions and Reprints

Zusammenfassung

Die Innovationen in der Therapie rheumatischer Erkrankungen haben die Lebensqualität vieler PatientInnen deutlich verbessert, sodass mehr Frauen ihren Kinderwunsch planen und realisieren können. In diesem Artikel werden die Erfahrungen zu Antirheumatika in der Schwangerschaft zusammenfassend dargestellt und Empfehlungen für den klinischen Alltag gegeben.

Die Beratung zum Arzneimittelrisiko muss 2 verschiedenen Situationen Rechnung tragen: der Einschätzung einer Arzneitherapie bei ungeplanter Schwangerschaft und der geplanten Arzneistoffauswahl bei Kinderwunsch bzw. in der Schwangerschaft. Für eine individuelle Risiko-Nutzen-Einschätzung sind, neben der Vorgeschichte der Patientin, Kenntnisse zum möglichen Risiko und Erfahrungsumfang der Arzneistoffe erforderlich sowie zu Besonderheiten und Verlauf der jeweiligen rheumatischen Erkrankung in der Schwangerschaft. Das Pharmakovigilanz- und Beratungszentrum für Embryonaltoxikologie (PVZ Embryotox) bietet Beratungen zu Arzneimitteln in Schwangerschaft und Stillzeit an und unterstützt die behandelnden ÄrztInnen bei der Therapieauswahl und Risikoeinschätzung.

Summary

The innovations in the therapy of rheumatic diseases have significantly improved the quality of life of many patients. Therefore, more women can plan to have children or get pregnant. This article summarizes the experiences with antirheumatic drugs during pregnancy and provides recommendations for everyday clinical use. The counselling has to deal with 2 different situations: the risk assessment of a drug therapy in an unplanned pregnancy and the planned selection of a drug before or during pregnancy. In addition to the medical history of the patient, an individual risk-benefit assessment requires knowledge of the possible risk and scope of experience of the drugs as well as of the special features and course of the respective rheumatic disease during pregnancy. The “Pharmakovigilanz- und Beratungszentrum für Embryonaltoxikologie” (PVZ Embryotox) offers advice on drugs in pregnancy and lactation and supports the treating physicians in the selection of therapies and risk assessment.

Schlüsselwörter

Schwangerschaft - Antirheumatika - Arzneimitteltherapiesicherheit - human - Tumornekrosefaktor-alpha-Inhibitor

Keywords

Pregnancy - antirheumatic agents - drug safety - human - tumor necrosis factor-alpha inhibitor
 

  • Literatur

  • 1 EUROCAT. Prevalence Tables (2018). Im Internet: http://www.eurocat-network.eu/accessprevalencedata/prevalencetables Stand: 5/07/2019
  • 2 Hoeltzenbein M, Elefant E, Vial T. et al Teratogenicity of mycophenolate confirmed in a prospective study of the European Network of Teratology Information Services.. Am J Med Genet A 2012; 158 A: 588-596 doi:10.1002/ajmg.a.35223 [doi]
    Google Scholar
  • 3 Weber-Schoendorfer C, Chambers C, Wacker E. et al Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study.. Arthritis Rheumatol 2014; 66: 1101-1110 doi:10.1002/art.38368 [doi]
    CrossrefPubMedGoogle Scholar
  • 4 Weber-Schoendorfer C, Oppermann M, Wacker E. et al Pregnancy outcome after TNF-alpha inhibitor therapy during the first trimester: a prospective multicentre cohort study.. Br J Clin Pharmacol 2015; 80: 727-739 doi:10.1111/bcp.12642 [doi]
    CrossrefPubMedGoogle Scholar
  • 5 Hoeltzenbein M, Weber-Schoendorfer C, Borisch C. et al Pregnancy outcome after paternal exposure to azathioprine/6-mercaptopurine.. Reprod Toxicol 2012; 34: 364-369 doi:S0890-6238(12)00078–0 [pii];10.1016/j.reprotox.2012.05.001 [doi]
    CrossrefPubMedGoogle Scholar
  • 6 Weber-Schoendorfer C, Schaefer C. Pregnancy outcome after tocilizumab therapy in early pregnancy – a case series from the German Embryotox Pharmacovigilance Center.. Reprod Toxicol 2016; 60: 29-32 doi:10.1016/j.reprotox.2016.01.002
    CrossrefPubMedGoogle Scholar
  • 7 Weber-Schoendorfer C, Beck E, Tissen-Diabate T. et al Leflunomide – A human teratogen? A still not answered question. An evaluation of the German Embryotox pharmacovigilance database.. Reprod Toxicol 2017; 71: 101-107 doi:10.1016/j.reprotox.2017.04.007
    CrossrefPubMedGoogle Scholar
  • 8 Weber-Schoendorfer C, Hoeltzenbein M, Wacker E. et al No evidence for an increased risk of adverse pregnancy outcome after paternal low-dose methotrexate: an observational cohort study.. Rheumatology (Oxford) 2014; 53: 757-763 doi:ket390 [pii];10.1093/rheumatology/ket390 [doi]
    CrossrefPubMedGoogle Scholar
  • 9 Hoeltzenbein M, Stieler K, Panse M. et al Allopurinol Use during Pregnancy – Outcome of 31 Prospectively Ascertained Cases and a Phenotype Possibly Indicative for Teratogenicity.. PloS one 2013; 8: e66637 doi:10.1371/journal.pone.0066637
    CrossrefPubMedGoogle Scholar
  • 10 Singh S, Sedgh G, Hussain R. Unintended pregnancy: worldwide levels, trends, and outcomes.. Stud Fam Plann 2010; 41: 241-250
    CrossrefPubMedGoogle Scholar
  • 11 de Man YA, Bakker-Jonges LE, Goorbergh CM. et al Women with rheumatoid arthritis negative for anti-cyclic citrullinated peptide and rheumatoid factor are more likely to improve during pregnancy, whereas in autoantibody-positive women autoantibody levels are not influenced by pregnancy.. Ann Rheum Dis 2010; 69: 420-423 doi:ard.2008.104331 [pii];10.1136/ard.2008.104331 [doi]
    CrossrefPubMedGoogle Scholar
  • 12 Zbinden A, van den Brandt S, Ostensen M. et al Risk for adverse pregnancy outcome in axial spondyloarthritis and rheumatoid arthritis: disease activity matters. Rheumatology (Oxford) 2018 doi:10.1093/rheumatology/key053. doi:10.1093/rheumatology/key053
    PubMed
  • 13 Marker-Hermann E, Fischer-Betz R. Rheumatic diseases and pregnancy.. Current opinion in obstetrics & gynecology 2010; 22: 458-465 doi:10.1097/GCO.0b013e3283404d67
    CrossrefPubMedGoogle Scholar
  • 14 Buyon JP, Kim MY, Guerra MM. et al Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study.. Ann Intern Med 2015; 163: 153-163 doi:10.7326/m14-2235
    CrossrefPubMedGoogle Scholar
  • 15 Fischer-Betz R, Specker C. Pregnancy in systemic lupus erythematosus and antiphospholipid syndrome.. Best practice & research Clinical rheumatology 2017; 31: 397-414 doi:10.1016/j.berh.2017.09.011
    CrossrefPubMedGoogle Scholar
  • 16 Goffman D, Cole DS, Bobby P. et al Failed methotrexate termination of pregnancy: a case report.. J Perinatol 2006; 26: 645-647 doi:10.1038/sj.jp.7211563
    CrossrefPubMedGoogle Scholar
  • 17 Adam MP, Manning MA, Beck AE. et al Methotrexate/Misoprostol Embryopathy: Report of four cases resulting from failed medical abortion.. Am J Med Genet 2003; 123 A: 72-78 doi:10.1002/ajmg.a.20503
    Google Scholar
  • 18 Fischer-Betz R, Specker C, Brinks R. et al Low risk of renal flares and negative outcomes in women with lupus nephritis conceiving after switching from mycophenolate mofetil to azathioprine.. Rheumatology (Oxford) 2013; 52: 1070-1076 doi:10.1093/rheumatology/kes425
    CrossrefPubMedGoogle Scholar
  • 19 [Anonym]. NTP Monograph: Developmental Effects and Pregnancy Outcomes Associated With Cancer Chemotherapy Use During Pregnancy. NTP monograph 2013. i-214
  • 20 Chambers CD, Johnson DL, Robinson LK. et al Birth outcomes in women who have taken leflunomide during pregnancy.. Arthritis Rheum 2010; 62: 1494-1503 doi:10.1002/art.27358 [doi]
    CrossrefPubMedGoogle Scholar
  • 21 Berard A, Zhao JP, Shui I. et al Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes.. Ann Rheum Dis 2018; 77: 500-509 doi:10.1136/annrheumdis-2017-212078
    CrossrefPubMedGoogle Scholar
  • 22 Cassina M, Johnson DL, Robinson LK. et al Pregnancy outcome in women exposed to leflunomide before or during pregnancy.. Arthritis Rheum 2012; 64: 2085-2094 doi:10.1002/art.34419 [doi]
    CrossrefPubMedGoogle Scholar
  • 23 Clowse MEB, Scheuerle AE, Chambers C. et al Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database.. Arthritis Rheumatol 2018; 70: 1399-1407 doi:10.1002/art.40508
    Google Scholar
  • 24 Carman WJ, Accortt NA, Anthony MS. et al Pregnancy and infant outcomes including major congenital malformations among women with chronic inflammatory arthritis or psoriasis, with and without etanercept use.. Pharmacoepidemiol Drug Saf 2017; 26: 1109-1118 doi:10.1002/pds.4261
    CrossrefPubMedGoogle Scholar
  • 25 Broms G, Granath F, Ekbom A. et al Low Risk of Birth Defects for Infants Whose Mothers are Treated with Anti-tumor Necrosis Factor Agents During Pregnancy.. Clin Gastroenterol Hepatol 2015; 14: 234-241 e231-235. doi:S1542-3565(15)01204–5 [pii];10.1016/j.cgh.2015.08.039 [doi]
    PubMedGoogle Scholar
  • 26 Julsgaard M, Christensen LA, Gibson PR. et al Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection.. Gastroenterology 2016; 151: 110-119 doi:https://doi.org/10.1053/j.gastro.2016.04.00227
    CrossrefPubMedGoogle Scholar
  • 27 Mahadevan U, Wolf DC, Dubinsky M. et al Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease.. Clin Gastroenterol Hepatol 2013; 11: 286-292 doi:S1542-3565(12)01408–5 [pii];10.1016/j.cgh.2012.11.011 [doi]
    CrossrefPubMedGoogle Scholar
  • 28 Zelinkova Z, de Haar C, de Ridder L. et al High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy.. Aliment Pharmacol Ther 2011; 33: 1053-1058 doi:10.1111/j.1365-2036.2011.04617.x [doi]
    CrossrefPubMedGoogle Scholar
  • 29 Murashima A, Watanabe N, Ozawa N. et al Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infant’s serum.. Ann Rheum Dis 2009; 68: 1793-1794 doi:68/11/1793 [pii];10.1136/ard.2008.105924 [doi]
    CrossrefPubMedGoogle Scholar
  • 30 Berthelsen BG, Fjeldsoe-Nielsen H, Nielsen CT. et al Etanercept concentrations in maternal serum, umbilical cord serum, breast milk and child serum during breastfeeding.. Rheumatology (Oxford) 2010; 49: 2225-2227 doi:keq185 [pii];10.1093/rheumatology/keq185 [doi]
    CrossrefPubMedGoogle Scholar
  • 31 Cheent K, Nolan J, Shariq S. et al Case Report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn’s disease.. J Crohns Colitis 2010; 4: 603-605 doi:10.1016/j.crohns.2010.05.001
    CrossrefPubMedGoogle Scholar
  • 32 Luu M, Benzenine E, Doret M. et al Continuous Anti-TNFalpha Use Throughout Pregnancy: Possible Complications For the Mother But Not for the Fetus. A Retrospective Cohort on the French National Health Insurance Database (EVASION). The American journal of gastroenterology 2018 doi:10.1038/s41395-018-0176-7. doi:10.1038/s41395-018-0176-7
    PubMed
  • 33 van den Brandt S, Zbinden A, Baeten D. et al Risk factors for flare and treatment of disease flares during pregnancy in rheumatoid arthritis and axial spondyloarthritis patients.. Arthritis research & therapy 2017; 19: 64 doi:10.1186/s13075-017-1269-1
    CrossrefPubMedGoogle Scholar
  • 34 Forger F, Bandoli G, Luo Y. et al Discontinuing TNF-inhibitors before gestational week 20 in well-controlled rheumatoid arthritis and juvenile arthritis is not associated with a disease worsening in late pregnancy. Arthritis Rheumatol 2019 doi:10.1002/art.40821. doi:10.1002/art.40821
    PubMed
  • 35 Hoeltzenbein M, Beck E, Rajwanshi R. et al Tocilizumab use in pregnancy: Analysis of a global safety database including data from clinical trials and post-marketing data.. Seminars in arthritis and rheumatism 2016; 46: 238-245 doi:10.1016/j.semarthrit.2016.05.004
    CrossrefPubMedGoogle Scholar
  • 36 Clowse ME, Feldman SR, Isaacs JD. et al Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis.. Drug Saf 2016; 39: 755-762 doi:10.1007/s40264-016-0431-z
    CrossrefPubMedGoogle Scholar
  • 37 Kumar M, Ray L, Vemuri S. et al Pregnancy outcomes following exposure to abatacept during pregnancy.. Seminars in arthritis and rheumatism 2015; 45: 351-356 doi:10.1016/j.semarthrit.2015.06.016
    CrossrefPubMedGoogle Scholar
  • 38 Youngstein T, Hoffmann P, Gul A. et al International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors.. Rheumatology (Oxford) 2017; 56: 2102-2108 doi:10.1093/rheumatology/kex305
    CrossrefPubMedGoogle Scholar
  • 39 Chang Z, Spong CY, Jesus AA. et al Anakinra use during pregnancy in patients with cryopyrin-associated periodic syndromes (CAPS).. Arthritis Rheumatol 2014; 66: 3227-3232 doi:10.1002/art.38811
    Google Scholar
  • 40 Smith CJF, Chambers CD. Five successful pregnancies with antenatal anakinra exposure. Rheumatology (Oxford) 2018 doi:10.1093/rheumatology/key093. doi:10.1093/rheumatology/key093
    PubMed